Literature DB >> 35253815

Iron oxide nanoparticles as a drug carrier reduce host immunosuppression for enhanced chemotherapy.

Benqing Zhou1, Jinxing Liu1, Lu Wang2, Meng Wang3, Chong Zhao1, Haoyu Lin4, Yuanke Liang4, Rheal A Towner5, Wei R Chen2.   

Abstract

Chemotherapy is still regarded as the main modality for cancer treatment. However, it often suppresses the host immune system, resulting in limited therapeutic effects. It is desirable to design a novel chemotherapeutic agent to reduce the level of immunosuppression. Herein, we designed bovine serum albumin (BSA)-bioinspired iron oxide nanoparticles (IONPs) as a nanocarrier to load anticancer drug mitoxantrone (MTX) for enhanced chemotherapy of orthotopic breast cancer. The treatment with IONPs@BSA-MTX complexes increased CD3+CD4+ and CD3+CD8+ T lymphocytes more than free MTX. The complexes effectively restored the host immune system and exhibited a better anticancer efficacy than free MTX. It was worth noting that the BSA-inspired IONPs were a satisfactory contrast agent for magnetic resonance imaging of tumors and lymph nodes. Our work provides a novel strategy for enhanced chemotherapy with low levels of immunosuppression in the treatment of breast cancer and other cancers.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35253815      PMCID: PMC9001247          DOI: 10.1039/d1nr07750c

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  45 in total

1.  BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy.

Authors:  Benqing Zhou; Jun Song; Meng Wang; Xin Wang; Jielin Wang; Eric W Howard; Feifan Zhou; Junle Qu; Wei R Chen
Journal:  Nanoscale       Date:  2018-11-29       Impact factor: 7.790

2.  Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.

Authors:  Suah Yang; Man Kyu Shim; Woo Jun Kim; Jiwoong Choi; Gi-Hoon Nam; Jeongrae Kim; Jinseong Kim; Yujeong Moon; Han Young Kim; Jooho Park; Yoon Park; In-San Kim; Ju Hee Ryu; Kwangmeyung Kim
Journal:  Biomaterials       Date:  2021-04-01       Impact factor: 12.479

Review 3.  Nanotherapeutics to overcome conventional cancer chemotherapy limitations.

Authors:  Moorthi Chidambaram; R Manavalan; K Kathiresan
Journal:  J Pharm Pharm Sci       Date:  2011       Impact factor: 2.327

Review 4.  Doxil®--the first FDA-approved nano-drug: lessons learned.

Authors:  Yechezkel Barenholz
Journal:  J Control Release       Date:  2012-03-29       Impact factor: 9.776

5.  Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model.

Authors:  Huan Meng; Min Xue; Tian Xia; Zhaoxia Ji; Derrick Y Tarn; Jeffrey I Zink; Andre E Nel
Journal:  ACS Nano       Date:  2011-04-27       Impact factor: 15.881

6.  PEGylated PAMAM dendrimer-doxorubicin conjugate-hybridized gold nanorod for combined photothermal-chemotherapy.

Authors:  Xiaojie Li; Munenobu Takashima; Eiji Yuba; Atsushi Harada; Kenji Kono
Journal:  Biomaterials       Date:  2014-05-09       Impact factor: 12.479

7.  Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy.

Authors:  Chih-Sheng Chiang; Yu-Jung Lin; Rachel Lee; Yen-Ho Lai; Hung-Wei Cheng; Chia-Hung Hsieh; Woei-Cherng Shyu; San-Yuan Chen
Journal:  Nat Nanotechnol       Date:  2018-05-14       Impact factor: 39.213

8.  Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.

Authors:  Yuanzeng Min; Kyle C Roche; Shaomin Tian; Michael J Eblan; Karen P McKinnon; Joseph M Caster; Shengjie Chai; Laura E Herring; Longzhen Zhang; Tian Zhang; Joseph M DeSimone; Joel E Tepper; Benjamin G Vincent; Jonathan S Serody; Andrew Z Wang
Journal:  Nat Nanotechnol       Date:  2017-06-26       Impact factor: 39.213

9.  Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators.

Authors:  Haitao Sun; Tianzhu Yu; Xin Li; Yangyang Lei; Jianke Li; Xiuhui Wang; Peike Peng; Dalong Ni; Xiaolin Wang; Yu Luo
Journal:  J Nanobiotechnology       Date:  2021-12-20       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.